Author: Business Wire

NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth

EMERYVILLE, Calif.–(BUSINESS WIRE)–$NBY #Avenova–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of who

Ocular Therapeutix™ Announces NDA Resubmission of DEXTENZA™

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate DEXTENZA™ (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmiss

BioTime Awarded Grant From the NIH

ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has been awarded a grant of $743,345 from the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH). This award constitutes the second-year funding of a $1.6 million SBIR grant to advance BioTime’s innovative, next generation retinal restoration program addressing advanced retinal diseases an

Novaliq’s NovaTears® Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealand

HEIDELBERG, Germany–(BUSINESS WIRE)–#AFT–Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced that NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD), is now also available in Australia. Dry eye is a chronic condition affecting about one third of Australian adults and half of those aged over 50. At a minimum, dry e

Global Ophthalmic Instrumentation Strategic Business Report 2018-2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Instrumentation – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin America. Annual estimates and forecasts are provided for the period 2015 through 2022. This report analyzes the worldwide markets in Units and US$ Thousand by the following Segments: Diagnostic Devices (OCT S